Literature DB >> 6711421

Intravenous streptokinase in evolving acute myocardial infarction.

W Ganz, I Geft, P K Shah, A S Lew, L Rodriguez, T Weiss, J Maddahi, D S Berman, Y Charuzi, H J Swan.   

Abstract

Eighty-one consecutive patients presenting within 3 hours of the onset of acute myocardial infarction (AMI) and without contraindications to thrombolytic or anticoagulant therapy received a 15- to 30-minute intravenous infusion of 750,000 or 1.5 million units of streptokinase (STK) followed by anticoagulation. Treatment was instituted 130 +/- 41 minutes after the onset of symptoms and reperfusion was achieved 36 +/- 26 minutes later. Reperfusion of the "infarct artery" was recognized by indirect clinical criteria in 78 patients (96%). In all 66 patients who underwent coronary angiography 3 to 7 days later, there was complete concordance between indirect and angiographic evidence of reperfusion. In 6 patients there was early reocclusion within 24 hours of treatment; in 4 of these patients, the artery was reopened with an additional dose of STK. Two elderly patients suffered an intracranial hemorrhage and there were 8 other major hemorrhagic complications, of which 7 were related to procedural trauma. Five patients (6.2%) died in the hospital. The results of intravenous STK thrombolytic therapy are compared with those of our previous study using intracoronary STK.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6711421     DOI: 10.1016/0002-9149(84)90066-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  29 in total

1.  Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.

Authors:  P Golino; J T Willerson
Journal:  Tex Heart Inst J       Date:  1991

2.  French multicenter trial of anistreplase versus heparin in acute myocardial infarction.

Authors:  H Lardoux; Y Louvard; D de Vernejoul; C Picot; M Baudet; M Hiltgen; M Houplon; J Ponsonnaille; M Richard; R Luccioni
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

3.  Acute tubular necrosis induced by coronary thrombolytic therapy.

Authors:  P A Kalra; A M Coady; A Iqbal; A Evans; S Waldek
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

4.  Association of coronary atherosclerotic burden with clinical presentation and prognosis in patients with stable and unstable coronary artery disease.

Authors:  Gjin Ndrepepa; Tomohisa Tada; Massimiliano Fusaro; Salvatore Cassese; Lamin King; Martin Hadamitzky; Hans-Ullrich Haase; Albert Schömig; Adnan Kastrati; Jürgen Pache
Journal:  Clin Res Cardiol       Date:  2012-07-08       Impact factor: 5.460

5.  Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.

Authors:  S Ikram; S Lewis; C Bucknall; I Sram; N Thomas; R Vincent; D Chamberlain
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-27

Review 6.  Medicine in the elderly.

Authors:  P Diggory; A Homer; J Liddle; C F Pratt; S Samadian; R Tozer; C Weinstein
Journal:  Postgrad Med J       Date:  1991-05       Impact factor: 2.401

7.  Thrombolytic therapy in the elderly.

Authors:  N J Dudley
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

8.  Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.

Authors:  J Owen; K D Friedman; B A Grossman; C Wilkins; A D Berke; E R Powers
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

9.  [Bolus injection of anisoylated plasminogen-streptokinase activator complex (BRL 26921) as an alternative concept of systemic lysis in acute myocardial infarct].

Authors:  P Doenecke; H Schwerdt; P Hellstern; E Wenzel; L Bette
Journal:  Klin Wochenschr       Date:  1986-08-01

10.  Efficacy and safety of a new streptokinase regimen with enoxaparin in acute myocardial infarction.

Authors:  Gabriel Tatu-Chitoiu; Cristina Teodorescu; Monica Dan; Petre Capraru; Manuela Guran; Oana Istratescu; Alexandrina Tatu-Chitoiu; Aurelia Bumbu; Maria Dorobantu
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.